Product image of Neisvac-C (N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid) supplied by GNH India

Neisvac-C

Active Ingredient:
N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid
Origin:
EU

Neisvac-C (N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid)

Neisseria meningitidis group C polysaccharide (de-O-acetylated) conjugated to tetanus toxoid, the active ingredient in Neisvac‑C, is a vaccine presented as a vaccine formulation for intramuscular use. It induces immunity to prevent invasive meningococcal disease caused by serogroup C in children, adolescents and adults, including high‑risk populations such as travelers to endemic regions.

GNH India supplies Neisvac‑C as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides cold‑chain logistics to ensure product integrity during global distribution.

Manufacturer / TM Owner

Pfizer Hellas A.E.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Neisvac‑C is a conjugate meningococcal vaccine that targets the polysaccharide capsule of Neisseria meningitidis serogroup C.

  • Prevention of invasive meningococcal disease caused by serogroup C: provides active immunity to reduce incidence of meningitis, septicemia and related complications.
  • Outbreak control in community settings: contributes to herd immunity and helps limit spread during serogroup C outbreaks.
  • Travel protection for individuals visiting endemic areas: offers prophylactic coverage against serogroup C exposure.

How It Works

  • Neisvac‑C contains the de‑O‑acetylated polysaccharide of Neisseria meningitidis group C covalently linked to tetanus toxoid. The conjugation converts the polysaccharide into a T‑cell‑dependent antigen, prompting robust B‑cell activation and high‑affinity IgG antibody production that neutralizes the bacterial capsule and facilitates opsonophagocytic clearance.

Side Effects

Neisvac‑C, like other conjugate vaccines, may be associated with local and systemic reactions after injection.

Common Side Effects

  • Injection site pain: mild to moderate discomfort at the injection site.
  • Redness or swelling: transient erythema or edema around the site.
  • Fever: low‑grade temperature elevation within 24‑48 hours.
  • Headache: mild headache commonly reported.
  • Fatigue: temporary tiredness following immunisation.
  • Myalgia: muscle aches may occur.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate medical attention.
  • Guillain‑Barré syndrome: rare immune‑mediated neuropathy.
  • Seizure: infrequent neurologic event.
  • Hypotension: sudden drop in blood pressure.
  • Immune‑mediated thrombocytopenia: low platelet count.
  • Severe allergic reaction: includes angioedema or respiratory distress.

Precautions & Warnings

Before administering Neisvac‑C, healthcare professionals should consider the following precautions.

  • Pregnancy: safety has not been established; vaccinate only if benefit outweighs potential risk.
  • Breastfeeding: weigh potential benefits for the infant against unknown risks.
  • Immunocompromised patients: vaccine may elicit a reduced immune response.
  • History of severe allergic reaction to any component of the vaccine: contraindicates use.
  • Concurrent administration with other vaccines: generally permissible but monitor for additive reactogenicity.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Neisvac‑C may interact with other medicines or biologics as follows.

Major Interactions (Avoid)

  • Concurrent administration of immunoglobulin or blood products within 4 weeks: may diminish vaccine‑induced immunity.
  • Live bacterial vaccines (e.g., BCG) given within 4 weeks before or after: may interfere with immune response.

Moderate Interactions (Monitor Closely)

  • Use of antipyretics (acetaminophen, ibuprofen) around vaccination: may mask fever but generally safe.
  • Immunosuppressive therapy (corticosteroids, chemotherapy): may reduce antibody production.
  • Pregnancy‑related hormonal changes: could modify immune response, monitor effectiveness.

Frequently Asked Questions

Neisvac‑C is a conjugate vaccine designed to prevent invasive disease caused by Neisseria meningitidis serogroup C. It is administered to individuals at risk of meningococcal infection, including children, adolescents, adults, and travelers to regions where serogroup C is prevalent.

The active ingredient is a de‑O‑acetylated polysaccharide from Neisseria meningitidis group C linked to tetanus toxoid. This conjugation creates a T‑cell‑dependent antigen that stimulates robust B‑cell responses, leading to high‑affinity IgG antibodies that neutralise the bacterial capsule and promote clearance.

The dosing schedule for Neisvac‑C is determined by the prescribing healthcare professional based on age, health status and local immunisation guidelines. No specific regimen is provided here; clinicians should follow the product label and regional recommendations.

Safety data for Neisvac‑C in pregnancy and lactation are limited. The vaccine should only be given if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare provider.

To place an order, submit an enquiry on the Neisvac‑C product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Neisvac‑C is a polysaccharide‑protein conjugate vaccine targeting serogroup C, offering a T‑cell‑dependent immune response that typically yields longer‑lasting immunity compared with plain polysaccharide vaccines. Other licensed meningococcal products may cover additional serogroups (A, W, Y, B) or use different carrier proteins.

Neisvac‑C must be stored refrigerated at 2‑8 °C. It should be kept in its original packaging, protected from light, and must not be frozen or shaken. Maintaining the cold chain during transport and storage is essential to preserve vaccine potency.

Neisvac‑C is given by intramuscular injection, typically into the deltoid muscle of the upper arm. The injection should be performed by a qualified healthcare professional using aseptic technique and following local immunisation protocols.

The most serious adverse events reported with Neisvac‑C include severe allergic reactions such as anaphylaxis, Guillain‑Barré syndrome, seizures, hypotension, and immune‑mediated thrombocytopenia. Any signs of a serious reaction require immediate medical evaluation.

Neisvac‑C is contraindicated in individuals with a known severe allergy to any component of the vaccine, including the tetanus toxoid carrier. Persons who have experienced a previous severe reaction to a meningococcal conjugate vaccine should also avoid this product.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT